Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Rational Vaccines Inc
Profile last edited on: 2/22/2024      CAGE: 87QU5      UEI: PKJWJVTMUS63

Business Identifier: Treatment, prevention, and diagnosis of herpes and herpes-related diseases
Year Founded
2018
First Award
2022
Latest Award
2023
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

8 Cabot Road Unit 3800
Woburn, MA 01901
   (781) 305-3600
   N/A
   www.rationalvaccines.com
Location: Single
Congr. District: 05
County: Essex

Public Profile

Describing themsleves as an investigational-stage infectious disease company, Rational Vaccines Inc is structured around combating those diseases that are the result of the herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$849,184
Phase II Dollars
$0
Total Awarded
$849,184

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $269,616
Project Title: A novel prophylactic and therapeutic vaccine for ocular herpes simplex virus infections
0 1 NIH $288,088
Project Title: Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections
0 1 NIH $291,480
Project Title: Development of a Highly Specific and Sensitive HSV-1 and HSV-2 Diagnostic Test

Key People / Management

  David Brindley -- Chief Regulatory & IP Officer

  Agustin Fernandez -- Chief Executive Officer

  Edward Gershburg -- Chief Technology Officer

  Gerhard Hager -- Head of Non-Clinical Development

  Olivier Jarry -- Chief Financial Officer

  Konstantin Kousoulas -- VP of Scientific Affairs

  Brandie Murphy -- Lab Manager

  Kerstin Westritschnig -- Chief Medical Officer

Company News

There are no news available.